Intracranial Hemorrhage from Meningioma: 2 Novel Risk Factors

Elliot Pressman1, David Penn2, Nirav J Patel2

  • 1Department of Neurosurgery and Brain Repair, University of South Florida, Tampa, Florida, USA.

World Neurosurgery
|November 8, 2019
PubMed
Abstract

Insights

Hemorrhage of benign brain tumors called meningiomas is rare. New potential risk factors for meningioma hemorrhage include serotonin-modulating therapy and high-dose estrogen replacement therapy.

Area of Science:

  • Neuro-oncology
  • Vascular Neurology

Background:

  • Meningiomas are the most common primary intracranial tumors.
  • Despite being slow-growing and vascular, meningioma hemorrhage is uncommon.
  • This study identifies novel modifiable risk factors for meningioma hemorrhage.

Observation:

  • A case of a 56-year-old female with a petroclival meningioma experiencing subarachnoid hemorrhage with intraventricular extension.
  • The patient was on escitalopram for depression and high-dose estrogen replacement therapy.
  • Postoperative complications included neurological decline, vasospasm, seizures, fever, and atrial fibrillation.

Findings:

  • Spontaneous meningioma hemorrhage is rare.
  • Established risk factors include age, tumor location, histopathology, hypertension, anticoagulation, and head trauma.
  • Serotonin-modulating therapy and high-dose estrogen replacement are proposed as novel risk factors.

Implications:

  • Clinicians should consider serotonin-modulating drugs and high-dose estrogen therapy as potential risk factors for meningioma hemorrhage.
  • Further research is warranted to validate these findings.
  • This may lead to improved patient management and risk stratification for meningioma patients.